"Kevetrin hits the tumors hard and fast and then exits the body; that's one of the beautiful attributes of this novel compound and what helps minimize toxicity," explained Ehrlich. "We saw some signs of tumor reduction with only one dose of Kevetrin per week in the Phase 1 study, while we better defined the safety profile. Armed with this data, we are going to get more aggressive at targeting tumors multiple times per week in Phase 2 research."